GlassScriptPhysician profile
Marissa N Largoza
NPI 1720183312
$6,066.99
in general payments reported to CMS, 2019-2025
37 companies · $763 in 2025
The $763 reported for 2025 was more than what 88% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $554 · 2020: $795 · 2021: $1,321 · 2022: $1,011 · 2023: $896 · 2024: $727 · 2025: $763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,385.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,576.56 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $702.45 | 2021-2025 | |
| Exeltis, USA INC. | $598.19 | 2019-2025 | Slynd |
| Shield Therapeutics INC | $496.28 | 2022-2025 | Accrufer |
| Evofem Biosciences, INC. | $348.87 | 2021-2025 | Phexxi, Solosec, Phexx |
| Daiichi Sankyo INC. | $285.30 | 2019-2022 | |
| Hologic Sales and Service, LLC | $192.10 | 2019-2025 | Aptima |
| Therapeuticsmd, INC. | $180.74 | 2019-2022 | |
| Myovant Sciences INC. | $171.70 | 2021-2022 | |
| Avion Pharmaceuticals | $165.13 | 2019-2023 | Balcoltra |
| Coopersurgical, INC. | $151.36 | 2020-2025 | Paragard T 380a, Paragard T 380a |
| Merck Sharp & Dohme LLC | $148.63 | 2019-2024 | Gardasil, Gardasil 9 |
| Sumitomo Pharma America, INC. | $130.03 | 2023-2025 | Myfembree |
| Roche Diagnostics Corporation | $102.12 | 2019-2020 | |
| Organon LLC | $84.13 | 2022-2025 | Nexplanon |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $79.93 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $62.30 | 2020-2021 | |
| Aspira Women'S Health INC | $61.95 | 2020-2024 | Ova1 |
| Vertical Pharmaceuticals, LLC | $56.00 | 2019-2020 | |
| Biogen, INC. | $51.58 | 2025 | Zurzuvae |
| Millicent US INC | $43.58 | 2019-2025 | Intrarosa, Femlyv |
| Pfizer INC. | $37.74 | 2023-2024 | |
| Duchesnay USA Incorporated | $36.99 | 2019 | |
| Minerva Surgical, INC | $34.37 | 2019 | |
| Astellas Pharma US INC | $33.34 | 2019-2024 | Veozah |
| Agile Therapeutics, INC. | $31.06 | 2021 | |
| Covidien LP | $29.77 | 2019-2020 | |
| Mylan Pharmaceuticals INC. | $29.26 | 2019-2021 | |
| Allergan, INC. | $25.18 | 2020 | |
| Si-Bone, INC. | $22.14 | 2024 | |
| Glaxosmithkline, LLC. | $21.25 | 2023 | Shingrix, Arexvy |
| Urovant Sciences INC | $16.71 | 2022 | |
| Sanofi Pasteur INC. | $15.99 | 2019 | |
| Davol INC. | $14.28 | 2024 | Arista Ah Flexitip |
| Kerecis Limited | $13.10 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Trevena, INC. | $12.14 | 2021 | |
| Acessa Health INC. | $4.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marissa Largoza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.